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Background
Metastatic melanoma has a poor prognosis, and 5-year
survival is 65% with regional stage disease and 15% with
distant stage disease. Chemotherapy has limited success
in metastatic melanoma, with a median overall survival
of 8 months. Malignant melanoma is not a singular,
homogeneous disease but rather a mixture of subtypes
characterized by specific mutations. Tumours with
BRAF mutations respond to BRAF kinase inhibitor
vemurafenib, that was approved by US FDA in 2011 and
EMA in 2012 for therapy of patients with advanced mel-
anoma, harboring mutation in BRAF V600E gene. Some
randomized clinical trials focused on the significant
reduction in the risk of death and disease progression
associated with vemurafenib, compared with classical
standard chemotherapy. Vemurafenib is generally well
tolerated with the most common side effects being
arthralgia, photosensitivity, fatigue and dermatitis.
Materials and methods
From January 2013 to August 2014 we have collected
data of 16 patients with metastatic melanoma (IV stage).
Metastatic sides were: brain (35%), liver (29%), skin
(24%) and lung (22%). We estimated overall survival
(OS) and toxicities therapy-related. Patients were eligible
if their tumour tissue was positive for the presence of
BRAF V600E mutation. Dosing of vemurafenib ranged
from 480 mg/bid to 960 mg/bid. Each patient has been
revalued every two weeks with clinical examination until
conclusion of treatment. Treatment was discontinued
on disease progression or toxicity.
Results
Median overall survival was 13 months. The most com-
mon adverse effects included arthralgia (40%), fatigue
(35%) and photosensitivity reactions (25%), grade 1 or 2
side effects as per the Common Terminology Criteria
for Adverse Events (CTCAE). Elevated liver enzymes
were documented in close to 10% of treated patients
and no prolongation of the QTc interval, cardiac
arrhythmias, keratoacanthoma and squamous cell carci-
noma were reported. Dosing’s modification has been
required in three patients: two patients have discontin-
ued the treatment and they have been resumed at 720
mg/bid while one patient have been resumed at 480
mg/bid. Nobody needed to stop the treatment due to
unacceptable toxicities.
Conclusions
According to the findings available in literature, inhibition
of BRAF improves clinical outcome in patients with the
BRAF V600E mutation. Vemurafenib was well tolerated
and adverse event profiles were similar to those reported
in literature.
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